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a b s t r a c t
We report a new series of 8-membered benzo-fused lactams that inhibit cellular lipid uptake from HDL
particles mediated by Scavenger Receptor, Class B, Type I (SR-BI). The series was identiﬁed via a high-
throughput screen of the National Institutes of Health Molecular Libraries Small Molecule Repository
(NIH MLSMR), measuring the transfer of the ﬂuorescent lipid DiI from HDL particles to CHO cells
overexpressing SR-BI. The series is part of a previously reported diversity-oriented synthesis (DOS) library
prepared via a build-couple-pair approach. Detailed structure–activity relationship (SAR) studies were
performed with a selection of the original library, as well as additional analogs prepared via solution
phase synthesis. These studies demonstrate that the orientation of the substituents on the aliphatic ring
have a critical effect on activity. Additionally, a lipophilic group is required at the western end of the
molecule, and a northern hydroxyl group and a southern sulfonamide substituent also proved to be
optimal. Compound 2p was found to possess a superior combination of potency (av IC50 = 0.10 lM)
and solubility (79 lM in PBS), and it was designated as probe ML312.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Cholesterol has been widely recognized to have a critical impact
on cardiovascular health. Our understanding of the connection
between plasma cholesterol levels and adverse cardiovascular
events has beneﬁted tremendously from the identiﬁcation of the
proteins and macromolecular complexes involved in cholesterol
biosynthesis and transport. This basic research has supported the
development of numerous pharmacological interventions, includ-
ing the development of HMG-CoA reductase inhibitors (statins),
which lower LDL-C (low-density lipoprotein cholesterol) and
decrease substantially the risk of adverse events and death in
patients with high levels of LDL-C.
Despite the identiﬁcation of the key players involved in choles-
terol biosynthesis and transport, our mechanistic understanding of
how these pathways are regulated is lacking in some important
details. For example, it is now apparent that simply elevating
HDL-C (high density lipoprotein cholesterol) levels may not
necessarily be beneﬁcial, despite a positive clinical correlation
between HDL-C levels and cardiovascular outcomes. The receptor
for HDL particles, Scavenger Receptor class B, type I (SR-BI),1,2 is
one of many Pattern Recognition Receptors and is important for
the uptake of HDL-C into liver cells (hepatocytes).3 Inhibition of
SR-BI has been explored in animal models as a means to boost
plasma HDL-C levels, but early results suggest that this approach
is counterproductive as a means to improve cardiovascular
health.3,4 Conversely, SR-BI is a co-receptor for the entry of patho-
gens into hepatocytes, including Hepatitis C virus (HCV)5–7 and
malaria (plasmodium) parasites8,9 and its inhibition has recently
been explored as a strategy for HCV patients requiring liver
transplant.10,11
Though it is now recognized as an important target for the
study of lipid metabolism and infectious disease, as well as
immune response12–14 and female fertility,3 the structure and
mechanism of SR-BI is not understood in full detail.15–18 In an
effort to identify novel small molecule modulators of this receptor
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that may exert unique effects on lipid transport, as well as
more potent and less toxic compounds, we embarked on a high-
throughput screen (HTS) supported by the NIH Molecular
Libraries Program (MLP). We recently reported two classes of
inhibitors from this screen with distinct advantages over prior
inhibitors identiﬁed in our laboratories.19 This work culminated
in the nomination of ML27820,21 and ML27922,23 as Molecular
Libraries probes. Other small molecule inhibitors of SR-BI have
been disclosed, including those from the labs of Sankyo4 and
iTherX.24–28 We report here a third class of inhibitors identiﬁed
from a diversity-oriented synthesis (DOS) library, somemembers of
which form a subset of the NIH Molecular Libraries Small Molecule
Repository. Screening and assay data for this project are also
publicly available in the PubChem database (http://pubchem.
ncbi.nlm.nih.gov/). The primary assay involved measuring the
uptake of the ﬂuorescent lipid 1,10-dioctadecyl-3,3,30,30-tetram-
ethylindocarbocyanine perchlorate (DiI) from DiI-labeled HDL par-
ticles into CHO cells overexpressing mouse SR-BI (ldlA[mSR-BI]).22
3046 compounds (0.96%) were classiﬁed as inhibitors of DiI-HDL
uptake out of 319,533 compounds tested, with inhibition at
12.5 lM ofP70% of the level inhibition with 1 lM BLT-1 (positive
control). Hit compounds were omitted that were on plates with
Z0<0.3 or that were active in 10% or more of the HTS assays listed
in PubChem. A counterscreen was also performed that rejected
hit compounds that quenched the ﬂuorescence of DiI-HDL in a
dose-dependent manner.
One of the more promising scaffolds that emerged from this
screen was the benzo-fused lactam represented by compound 1a
(Table 1). 1a and related compounds had been prepared as part
of a diversity-oriented synthesis (DOS) library, with a SNAr reaction
as the key ring-forming step (Scheme 1).29 Since only a selection of
the original DOS library had been included in our primary assay,
we began our follow-up studies by testing DMSO stock solutions
of each of the stereoisomers of 1a for activity. The 2R, 5R, 6R stereo-
chemistry of 1a provided the best results (Table 1); compounds
Table 1
SSAR of lead compound 1a
Me
(R) OHN
(R)
Me(R)O
H
N
O
N
Me
S
O O
Cl
O
2
5
6
1a
N
Me
Compd Stereochem. IC50a (lM) Compd Stereochem. IC50a (lM)
1a 2R, 5R, 6R 0.18 1ae 2S, 5S, 6S 17.4
1ab 2R, 5R, 6S 11.5 1af 2S, 5S, 6R 12.3
1ac 2R, 5S, 6R >25 1ag 2S, 5R, 6S 10.0
1ad 2S, 5R, 6R 0.91 1ah 2R, 5R, 6S 8.9
a Average of at least two measurements in DiI uptake assay with DMSO stock
solutions.
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Scheme 1. Previous synthesis of core scaffold for library synthesis via SNAr reaction.
Table 2
SAR of southern amine substituent
Me
OHN
MeO
H
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N
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ON
Me
R1
Compd R1 IC50a
(lM)
Compd R1 IC50a
(lM)
1a S
O
O
Cl
0.46 1j
H
>25
1b
S
O
O
F
0.56 1k
Me
18
1c
S
O
O
OMe
2.0 1l 9.2
1d S
O
O
0.22 1m 1.6
1e S
O
O
S
2.4 1n OMe 2.6
1f
S
O
O
N
N
Me
6.4 1o CF3 0.65
1g
Me
S
O
O
9.9 1p
Cl
Cl
>25
1h N
H
O
4.9 1q O
O
0.89
1i
N
H
O
9.2 1r N 1.3
a Average of at least two measurements in DiI uptake assay with resynthesized or
repuriﬁed compounds.
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with different stereochemistry at the carbons of the 8-membered
ring (carbons 5 and 6 according to our convention29) suffered from
a sizable drop in potency. Inversion of stereochemistry at the 2-
position caused a less substantial drop in activity (compound 1ad).
Full SAR studies continued with reverse-phase HPLC repuriﬁca-
tion of a large number analogs of 1a with the 2R, 5R, 6R stereo-
chemistry. First, the substituents of the southern amine were
examined. A selection of these results is given in Table 2. Our lead
compound, 4-chlorophenylsulfonamide 1a, inhibited DiI-HDL
uptake with IC50 = 0.46 lM when retested as a puriﬁed dry pow-
der. The 4-ﬂuorophenyl analog 1b was comparable in potency
(IC50 = 0.56 lM), but the larger and more electron-rich 4-methoxy
analog 1c suffered a signiﬁcant decrease in potency (IC50 = 2.0 lM).
The unsubstituted benzenesulfonamide 1d also showed good
potency, but in early assays it was not superior to the 4-chloro ana-
log 1a. Interestingly, thiophene 1e was not a useful isostere
(IC50 = 2.4 lM). One liability of 1a is its low solubility (0.1 lM in
PBS with 1% DMSO). The imidazole analog 1f possessed good
solubility (79 lM), but was only weakly potent (IC50 = 6.4 lM).
The truncated methylsulfonamide 1g also showed good solubility
but weak potency. A series of ureas from the original DOS library
(including 1h and 1i) were mediocre inhibitors. Many amine com-
pounds with both small (1j, 1k) and larger (1l, 1m, 1n, 1p, 1r)
N-alkyl substituents were also mediocre, though the 4-CF3 benzyl
analog 1o showed moderate levels of inhibition (IC50 = 0.65 lM).
Keeping the southern 4-chlorophenylsulfonamide of 1a in
place, we proceeded to test analogs with variable substitutions at
the western nitrogen (Table 3). This region is very sensitive to
modiﬁcation, as moving from the cyclohexyl amide 2e
(IC50 = 0.054 lM), to the less bulky and lipophilic cyclopropyl
amide 2g (IC50 = 2.1 lM), gave a nearly 40-fold drop in potency.
It is evident that lipophilic, uncharged substituents are highly pre-
ferred at this location. The triﬂuoromethyl substituted amide 2b
showed moderate inhibition (IC50 = 0.26 lM), but molecules with
terminal oxygens or nitrogens that can be protonated or accept
hydrogen bonds were poor inhibitors (2c, 2d, 2f, 2h, 2n). The lone
Table 3
SAR of western amine substituent
Me
OHN
MeO
H
NR2
O
N
Me
S
O O
Cl
Compd R1 IC50a (lM) Compd R1 IC50a (lM)
1a
ON
Me
0.46 2l
H
N
O
F
0.092
2b
O
F3C 0.26 2m
H
N
O
MeO
0.30
2c O
Me2N >25 2n
H
N
OO
N
Me
Me
7.1
2d
O
N
O
5.0 2o
H
N
O
0.35
2e
O
0.054 2p
H
N
O
Me
Me
0.10 ± 0.02b
2f
O
O
>25 2q
S
Me
O O 1.6
2g
O
2.1 2r S
O O
3.2
2h O
N
NN
N 10 2s
S
O O
F
14
2i
H
N
O >25 2t S
O O
N
O
Me
Me
0.19
a Average of at least two measurements in DiI uptake assay with resynthesized or repuriﬁed compounds.
b Standard error of mean, N = 3.
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exceptions observed were the isoxazole sulfonamide 2t
(IC50 = 0.19 lM), which has a unique steric and electronic environ-
ment about its terminal nitrogen, and the 4-methoxyphenyl urea
2m (IC50 = 0.30 lM). Several other ureas also showed good activity,
including 2l (IC50 = 0.092 lM), 2o (IC50 = 0.35 lM), and the
isopropyl urea 2p (IC50 = 0.10 lM). Several sulfonamides at this
position that were tested showed weak inhibition (2q to 2s).
Interestingly, the highly simpliﬁed N,N-dimethylaniline 8
(Table 4) gave modest inhibition (IC50 = 0.63 lM).
To obtain additional insights into the functionality and
structural requirements for inhibition of SR-BI, several additional
analogs were prepared and tested during the course of this project
(Table 4). Changing the position on the benzene ring of the western
amine substituent gave an inactive analog (3) of isopropyl urea 2p.
Expansion of the lactam scaffold from an 8-membered ring to a
9-membered ring (4) also abrogated the activity. Further investiga-
tion of the southern nitrogen substituent indicated that a sulfon-
amide is optimal, as the southern amide analog 5 of sulfonamide
2e was inactive. The position of the chlorine substituent was also
examined with respect to the western cyclohexyl amide 2e.
3-Chloro (6, IC50 = 0.80 lM) and 2-chlorophenyl (7, IC50 = 0.18
lM) analogs showed decreased inhibition relative to 2e.
The hydroxyl group present in all compounds reported thus far
served as an anchor for attachment of the DOS scaffolds to a solid
support for library preparation,30 and also for attachment of library
compounds to solid surfaces for small molecule microarray
screens.31 Therefore, the SAR around this region remained
unexplored. Treatment of 1a with DPPA and DBU, followed by
Staudinger reduction with triphenylphosphine in THF/water,
provided primary amine 9, which proved to be inactive.
Displacement of the intermediate azide with dimethylamine gave
the tertiary amine 10, which was also inactive. The methyl ether
analog of 2p was also prepared and found to be only weakly active
(11). Limited attempts at reductive deoxygenation of 2p were
unsuccessful, so the deoxy analog 12 was prepared via a de novo
route (see Supporting information) and also found to have weak
activity, suggesting that the hydroxyl group is required for sub-
stantial inhibition of SR-BI with this scaffold.
The water solubility of the lead compound in this series (1a,
0.1 lM in PBS) was reminiscent of the poor water solubility of
Table 4
Various analogs
Compd Structure IC50a (lM) Compd Structure IC50a (lM)
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MeO
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MeO
H
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Me
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O
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NMe
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Me
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H
N
O
N
Me
S
O O
O
Cl
0.18 12
Me
Me
N
MeO
H
N
O
N
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S
O O
Cl
O
H
NMe
Me 9.9
a Average of at least two measurements in DiI uptake assay.
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one of our previous probes (ML278, 0.57 lM in PBS). Fortunately,
several of the potent analogs screened in these studies showed
much higher solubility. In particular, the diisopropyl urea 2p
exhibited the best combination of potency (average
IC50 = 0.10 lM, Supporting information Fig. S1) and solubility
(79 lM in PBS). As this compound was present in our original
DOS library along with all its stereoisomers, we were able to con-
ﬁrm that the 2R, 5R, 6R stereochemistry of 2p is optimal, in line
with the results with 1a. 2p was nominated as Molecular
Libraries Probe ML312. Its re-synthesis is outlined in Scheme 2.
Ourmost promising compounds in this project were proﬁled in a
series of secondary assays to gain insights into their mode of action
and potential for further development. None of the compounds in
Tables 1–4 showed any measurable cytotoxicity after incubation
with the cell line used in our assays (ldlA[mSR-BI]) for 24 h, using
a CellTiter-Glo assay (Promega) to measure cellular ATP levels.
ML312 also exhibited excellent plasma stability, with >99%
remaining after 5 h incubation with human or mouse plasma.
Plasma protein binding (PPB) studies showed that it was 94.5%
bound in human plasma, and 94.7% bound in mouse plasma.
ML312 has limitedmetabolic stability, with 25% and 10% remaining
after incubation with mouse and human liver microsomes for 1 h.
Additional studies with ML312 were performed to study its
mode of action. In addition to measuring the uptake of DiI from
DiI-HDL in the presence of ML312, the uptake of [3H]-labeled cho-
lesteryl oleate ester ([3H]CE) was measured. ML312 inhibited
[3H]CE uptake with a measured IC50 of 0.25 lM (Supporting infor-
mation Fig. S2), a result superior to the clinical compound ITX-
5061, but inferior to our alternative probes ML278 and ML279.
The binding of Alexa-488-labeled HDL particles to ldlA[mSR-BI]
cells via SR-BI was also measured. As with our prior probes,
ML312 enhanced the level of HDL binding to SR-BI, with an EC50
of 0.4 lM (Supporting information Fig. S3), a phenomenon that
we have observed previously.21 One possibility is that such com-
pounds act to inhibit lipid transport by preventing release of the
bound HDL particles from the receptor. Finally, to determine if
ML312 might have inhibited SR-BI-mediated lipid uptake by block-
ing receptor-mediated endocytosis, the endocytosis of Alexa-594-
labeled transferrin was monitored. ML312 showed no inhibition
of endocytosis by ldlA[mSR-BI] cells at concentrations up to
35 lM. Additionally, binding studies were performed with a panel
of 67 different receptors and secondary targets (see Supporting
information for details). At a concentration of 10 lM, no targets
were inhibited by 20% or more, with the highest level of inhibition
observed with the L-type Ca2+ channel (19% inhibition). It thus
appears to have better selectivity than our previously reported
probe ML278, perhaps due to its multiple stereocenters and more
complex 3D structure.32
In summary, potent inhibitors of SR-BI-mediated lipid (DiI)
uptake were discovered as part of the NIH Molecular Libraries
Probe Production Centers Network (MLPCN) initiative. Proﬁling
and SAR analyses of several top compounds led to the nomination
of the benzo-fused lactam 2p (ML312) as a probe compound for
SR-BI.33 ML312 has superior solubility to the other probes identi-
ﬁed in this project, is not cytotoxic, has no signiﬁcant chemical lia-
bilities, and appears to act selectively at SR-BI, though it is less
potent than ML278 (IC50 = 6 nM) or ML279 (IC50 = 17 nM) in the
primary assay.
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